📰 Allarity News
Allarity News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Allarity. Real-time updates on events, politics, business and more.
April 17, 2023
CAMBRIDGE, MA / ACCESSWIRE / April 17, 2023 / Allarity Therapeutics (NASDAQ:ALLR) dosed its first patient in Phase 1b of its clinical trial for the novel combination therapy of two drugs, stenoparib and
March 24, 2023
Common Stock Will Begin Trading on a Post-Split Adjusted Basis on March 27, 2023 Press releaseBOSTON, Mass - March 24, 2023 - Allarity Therapeutics, Inc. (Nasdaq: ALLR) ("Allarity" or the "Company"), a
October 18, 2022
EQS-News: Allarity Therapeutics, Inc. Precision Medicine Could Get Even More Precise With Allarity Therapeutics’ “Next-Generation” Diagnostics Platform 18.10.2022 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Once brought into its pipeline, Allarity uses...
September 12, 2022
Press release Cambridge, MA U.S.A. — Allarity Therapeutics, Inc. , a clinical-stage pharmaceutical company developing novel oncology therapeutics together with... | September 12, 2022
April 23, 2022
Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250 Cambridge, MA U.S.A. - Allarity Therapeutics, Inc. , a clinical-stage... | April 22, 2022
April 22, 2022
Cambridge, MA U.S.A. (April 22, 2022) - Allarity Therapeutics, Inc. (Nasdaq: ALLR) ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together
December 13, 2021
Allarity Therapeutics A/S has applied for its shares to be delisted from Nasdaq First North Growth Market. Nasdaq Stockholm AB has approved the application and decided to delist the shares in Allarity
September 16, 2021
Patient selection using DRP score of 50% resulted in a median survival of 15.0 monthPatient selection using DRP score of 67% resulted in a median survival of 20.6 months Press Release Hørsholm
August 26, 2021
Press Release Hørsholm, Denmark – Allarity Therapeutics A/S today announces that an accelerated extraordinary and final exercise period for warrants of the ALLR TO 3 series , which... | August 27, 2021
June 4, 2021
On April 3, 2020, the shares in Allarity Therapeutics A/S (the "Company") (formerly known as Oncology Venture A/S) were given observation status with reference to a material adverse uncertainty in respect